Olmos, D., Postel-Vinay, S., Molife, L. R., Okuno, S. H., Schuetze, S. M., Paccagnella, M. L., . . . Haluska, P. (2009). Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing’s sarcoma: A phase 1 expansion cohort study.
Citação norma ChicagoOlmos, David, et al. Safety, Pharmacokinetics, and Preliminary Activity of the Anti-IGF-1R Antibody Figitumumab (CP-751,871) in Patients With Sarcoma and Ewing’s Sarcoma: A Phase 1 Expansion Cohort Study. 2009.
ציטוט MLAOlmos, David, et al. Safety, Pharmacokinetics, and Preliminary Activity of the Anti-IGF-1R Antibody Figitumumab (CP-751,871) in Patients With Sarcoma and Ewing’s Sarcoma: A Phase 1 Expansion Cohort Study. 2009.